Search

Your search keyword '"Frankel, Arthur"' showing total 1,111 results

Search Constraints

Start Over You searched for: Author "Frankel, Arthur" Remove constraint Author: "Frankel, Arthur"
1,111 results on '"Frankel, Arthur"'

Search Results

1. Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib

2. Machine learning for rhabdomyosarcoma histopathology

4. The 2023 US National Seismic Hazard Model: Subduction ground-motion models.

5. The 2023 US National Seismic Hazard Model: Ground-motion characterization for the conterminous United States

7. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

9. Correction to: Machine learning for rhabdomyosarcoma histopathology

11. The USGS 2023 Conterminous U.S. Time-Independent Earthquake Rupture Forecast

14. The 2023 US 50-State National Seismic Hazard Model: Overview and implications.

18. Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis

21. Supplementary Figures S1-S3 from Matrix Metalloproteinase–Activated Anthrax Lethal Toxin Inhibits Endothelial Invasion and Neovasculature Formation during In vitro Morphogenesis

22. Supplementary Data from Matrix Metalloproteinase–Activated Anthrax Lethal Toxin Inhibits Endothelial Invasion and Neovasculature Formation during In vitro Morphogenesis

23. The 2002 Denali Fault Earthquake, Alaska: A Large Magnitude, Slip-Partitioned Event

25. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

27. 3D Wave Propagation Simulations of Mw 6.5+ Earthquakes on the Tacoma Fault, Washington State, Considering the Effects of Topography, a Geotechnical Gradient, and a Fault Damage Zone.

31. Figure S1 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma

33. Supplementary Fig. S1 from Cytotoxicity of the matrix metalloproteinase–activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells

34. Supplementary Figure 2 from Inhibition of Tumor Angiogenesis by the Matrix Metalloproteinase–Activated Anthrax Lethal Toxin in an Orthotopic Model of Anaplastic Thyroid Carcinoma

36. Supplementary Figure 1 from Inhibition of Tumor Angiogenesis by the Matrix Metalloproteinase–Activated Anthrax Lethal Toxin in an Orthotopic Model of Anaplastic Thyroid Carcinoma

37. Supplementary Data Legends from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma

38. Table S1 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma

39. Tables S2-S9 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma

43. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need

44. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

46. Immunotoxins

49. Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review

Catalog

Books, media, physical & digital resources